<DOC>
	<DOCNO>NCT00603668</DOCNO>
	<brief_summary>This study test different dose anti-CD74 antibody patient NHL and/or CLL .</brief_summary>
	<brief_title>Phase I/II Study Different Doses Dose Schedules Milatuzumab ( hLL1 ) CLL</brief_title>
	<detailed_description>Milatuzumab ( hLL1 , IMMU-115 ) , humanize anti-CD74 monoclonal antibody . Dose escalation utilize 4 plan dose regimen 4.0 8.0 mg/kg dos administer intravenously either twice weekly ( day 1 4 ) thrice weekly ( day 1 , 3 5 ) 4 consecutive week . The four plan dose regimen label dose level 1 4 correspond increase level total dose milatuzumab .</detailed_description>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Histologically confirm diagnosis recurrent chronic lymphocytic leukemia ( NCI criterion ) Received least one prior treatment standard therapy ( previous antibody therapy acceptable ) Measurable disease ( WBC &gt; 5,000 CLL ) See protocol full list Pregnant lactate woman . Women childbearing potential must negative pregnancy test Pregnancy testing require postmenopausal surgically sterilize woman Women childbearing potential fertile men practice unwilling practice birth control enrol study least 12 week last milatuzumab infusion Prior therapy human humanize monoclonal antibody , unless HAHA test negative ; Bulky disease CT , define single mass &gt; 10 cm great diameter Known HIV positive active hepatitis B C , presence hepatitis B surface antigens presence hepatitis C antibody Known autoimmune disease presence autoimmune phenomenon At least 7 day beyond infection require antibiotic use . Systemic corticosteroid within 2 week , except low dose regimen ( prednisone , &lt; 20 mg/day , equivalent ) may continue unchanged . Substance abuse concurrent medical psychiatric condition , Investigator 's opinion , could confound study interpretation affect patient 's ability tolerate complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>CLL</keyword>
</DOC>